were amplified by PCR using the forward primer 5Ј-ATGCGCGCGCGGGCC CAACCTGTGGGTGACCGTG-3Ј and the backward primers described above. Enzymatic manipulations and cloning of the CON6 gp120 and CON6 gp140CF env genes into various plasmids were performed as described previously (22) . All constructs were confirmed by DNA sequencing.
Generation of recombinant M. smegmatis expressing HIV-1 envelope. All M. smegmatis cultures were grown in Middlebrook 7H9 broth (Difco) containing 10% albumin-dextrose saline (ADS)-0.5% glycerol-0.05% Tween 80 (7) . For generation of recombinant M. smegmatis, M. smegmatis mc 2 155 prepared in 10% glycerol was transformed with the constructed plasmids ( Table 1) by electroporation with a Gene Pulsar (Bio-Rad) set at 2.5 kV and 25 F and with the pulse controller resistance set at 1,000 ⍀ (23, 27) . Transformed M. smegmatis organisms were selected on Middlebrook 7H10 (Difco, Sparks, MD) agar plates supplemented with 10% ADS containing either 30 g/ml kanamycin or 20 g/ml hygromycin. To monitor the expression of HIV-1 gp120 or gp140CF, individual colonies of recombinant M. smegmatis grown in Middlebrook 7H9-ADS-Tween broth in the presence of 30 g/ml of kanamycin or hygromycin were harvested by centrifugation. After a rinse with sterile phosphate-buffered saline, mycobacterial cells were lysed by using the modified extraction buffer with 106-m glass beads (Sigma) (7) and cell lysates were cleared by centrifugation. The lysate of recombinant M. smegmatis was fractionated by 4 to 20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto nitrocellulose filters (Schleicher & Schuell, Germany). HIV-1 Env protein bands were detected by incubation of the filters with the monoclonal antibody (MAb) T8, 7B9, or 7B2 at 1 g/ml, followed by incubation with goat anti-mouse immunoglobulin G (IgG)-or goat anti-human IgG (Sigma, St. Louis, MO)-alkaline phosphatase. T8 is a mouse MAb that binds to the HIV-1 Env gp120 C1 region (a gift from Pat Earl, NIH, Bethesda, MD). 7B2 is a human MAb against the immunodominant region of the HIV-1 Env gp41 region and was a gift from James Robinson (Tulane Medical School, New Orleans, LA). 7B9 is a mouse IgG1 MAb made from murine B cells immunized with the 62.19 HIV-1 clade B V3 loop sequence (RPNNNTRK SIHIGPGRAFYATE) (18) that reacts with the CON6 gp120 V3 loop.
Mouse immunizations. Female BALB/c mice (6 to 8 weeks of age) were purchased from Charles River Laboratory (Raleigh, NC) and housed in the Duke Cancer Center Isolation Facility under AALAC guidelines with animal use protocols approved by the Duke University Animal Use and Care Committee and the Duke University Institutional Biosafety Committee. Mice were immunized either intraperitoneally (i.p.) or intradermally (i.d.) with recombinant M. smegmatis expressing CON6 gp120 or gp140CF using doses ranging from 10 7 to 10 10 CFU/mouse in 100 l of phosphate-buffered saline containing 0.05% Tween 80. For boosting immunizations with CON6 Env protein, 50 g of recombinant CON6-gp140CF oligomer (6) was mixed in an equal volume with RiBi adjuvant (Sigma) and administrated i.p. and subcutaneously (s.c.). After immunization, serum was collected for antibody assays every 2 weeks. Mouse spleen, lung, and FRT samples were harvested for evaluation of T-cell responses 10 days after the final immunization.
ELISA and antibody isotype analysis. Serum antibody titers against HIV-1 CON6-gp140CF or M. tuberculosis whole-cell lysate (WCL) (Colorado State University, Fort Collins, CO) were measured in a standard enzyme-linked immunosorbent assay (ELISA). For isotype analysis of serum antibodies, we used goat anti-mouse IgG (heavy chain specific), IgG1, IgG2a, IgG2b, IgG3, or IgM (Southern Biotechnology) as alkaline phosphatase-conjugated antibodies. Antibody endpoint titers were determined as the reciprocal of the highest dilution of the serum assayed against recombinant HIV-1 envelope proteins or M. tuberculosis WCL giving an optical density reading of experiment/control of Ն3 times over the background activity of prebleed serum samples. Geometric mean titers were determined based on the endpoint titer of each mouse serum. Statistical significance was assessed by Student's t test.
IFN-␥ ELISPOT assays.
ELISPOT assays were performed as described previously (20) . Briefly, 96-well flat-bottom plates (Millipore) were coated with an anti-mouse IFN-␥ capture antibody (Pharmingen). After the plates were blocked and washed, lymphocytes freshly isolated from the spleen, lungs, and FRT of immunized mice were added and incubated with a mixture of either 10 CON6-gp140 Env 15-mer peptides (for determining T-cell responses to the HIV-1 Env insert) that have been previously shown to represent CON6 Env epitopes recognized in BALB/c mice (6, 28 (Fig. 1A) . No HIV-1-specific protein bands were detected in untransformed M. smegmatis (Fig. 1A, lane 2) or recombinant M. smegmatis transformed with empty plasmid (lane 3). Figure 1A shows that the expression of the intact CON6 gp120 was detected in recombinant M. smegmatis transformed with either the surface expression plasmid pJH152 (Fig. 1A, lane 4) , the intracellular expression plasmid pJH153 (lane 5), or the secreted expression plasmid pJH154 (lane 6). Expression of CON6 gp140CF was also detected in recombinant M. smegmatis transformed with the surface expression plasmid pJH152 (lane 7) or pJH222 (lane 8). Both the intact and partially cleaved gp140 products were identified with the gp120-specific MAb T8 (anti-C1 gp120 region), the gp41-specific MAb 7B2, and V3 loop-specific MAb 7B9. The calculated nonglycosylated molecular masses based on amino acid sequences were 53 kDa for CON6 gp120 and 71 kDa for CON6 gp140CF. However, the protein bands of CON6 gp120 and CON6 gp140CF expressed in recombinant M. smegmatis were approximately 80 kDa and 90 kDa, respectively, suggesting that the CON6 gp120 and CON6 gp140CF proteins expressed in recombinant M. smegmatis were partially glycosylated. Figure 1B shows schematic representations of the full-length (top) and cleaved (bottom) CON6 gp140, with indications of the binding locations of MAbs T8, 7B2, and 7B9. In the cleaved gp140, MAb T8 reacted only with the 34-kDa protein band, while MAbs 7B2 and 7B9 reacted with the 49-kDa protein band (Fig. 1B) . These data suggest that the 49-kDa cleaved protein contained portions of the V3 loop region and the gp41 domain. In addition, analysis of the supernatant of recombinant M. smegmatis expressing secreted CON6 gp140 that was grown in Sauton liquid medium revealed that HIV-1 CON6 Env was produced as a truncated soluble protein containing the V3 loop in tissue culture supernatant, as detected by MAb 7B9 (Fig. 1C) .
Detection of HIV-1 envelope-specific IFN-␥ SFC in the spleen. Mice were immunized with recombinant M. smegmatis expressing HIV-1 gp120 as a secreted insert at doses ranging from 10 7 to 10 10 CFU at week 0 and week 8 via i.p. injections. Unimmunized mice were used as negative controls. Animals that were primed with rAd5 expressing CON6 Env (rAd-CON6) and boosted with rVV expressing CON6 Env (rVV-CON6) were used as positive controls. Splenocytes from animals primed once with recombinant M. smegmatis i.p. yielded no CON6 gp120-specific responses (Ͻ5 SFC/10 6 cells). The lack of response to a single immunization with recombinant M. smegmatis was consistent regardless of the concentration of recombinant M. smegmatis used (10 9 , 10 8 , 10 7 , or 10 6 CFU). When mice were boosted i.p. with recombinant M. smegmatis 8 weeks following the recombinant M. smegmatis prime, HIV-1 CON6 gp120-specific responses in spleens were easily detectable ( 6 cells) (P Ͻ 0.05, P Ͻ 0.01, and P Ͻ 0.01, respectively). Mice primed with rAd-CON6 and boosted with rVV-CON6, produced 201 Ϯ 89.6 IFN-␥ SFC/10 6 cells in lungs. We also found that after a prime and boost of recombinant M. smegmatis, CON6 peptide-specific responses were detectable in the mouse FRT (Fig. 2C) . Lymphocytes isolated from the FRT of mice that were primed and boosted with Untransformed M. smegmatis and recombinant M. smegmatis transformed with empty plasmid (pJH222) were used as negative controls. Immunogen groups were recombinant M. smegmatis expressing HIV-1 gp120 as full-length proteins (pJH152-gp120, pJH153-gp120, and pJH154-gp120) and recombinant M. smegmatis expressing HIV-1 gp140CF as full-length proteins and in cleaved forms (pJH152-gp140CF, pJH222-gp140CF, and pJH154-gp140CF). We found that immunization via the i.p. route ( Fig. 3A and C) was optimal for the induction of T-cell responses in comparison with i.d. immunization ( Fig. 3B and D) . In the spleen, optimal IFN-␥ SFC responses were seen in mice immunized i.p. with pJH154-gp120 or pJH154-gp140CF constructs, both engineered to secrete insert protein ( Fig. 3A and B ). An rAd-CON6 prime/ rVV-CON6 boost was used for comparison and showed an approximately fourfold-greater IFN-␥ ELISPOT response than did recombinant M. smegmatis pJH154-gp120 or pJH154-gp140 ( Fig. 3A and B) . In addition to this positive control, one group of mice was immunized with only the CON6 Env protein at the time all other groups were boosted with the CON6 Env protein. We found that immunization once with recombinant gp140CF Env induced no significant IFN-␥ SFC (7 Ϯ 3 SFC/ 10 6 cells), similar to what occurred with mice immunized with recombinant M. smegmatis transformed with empty plasmid and boosted with CON6 Env proteins. Thus, protein immunization did not augment T-cell responses to the recombinant M. smegmatis prime and boost.
Responses to the recombinant M. smegmatis vector itself in the spleen were also monitored and showed that i.p. immunization was superior to the i.d. route for induction of vector responses (Fig. 3C and D) . While boosting once with M. smeg-
FIG. 2. HIV-1 envelope-specific and vector-specific T-cell responses in the spleen, lungs, and FRT of mice immunized with recombinant M. smegmatis. HIV-1-specific (A to C) and vector-specific (D to F) T-cell responses in the spleen (A and D), lungs (B and E), and FRT (C and F)
were assessed by IFN-␥ ELISPOT assays. Mice that were primed with rAd-CON6 and boosted with rVV-CON6 were used as positive controls. Unimmunized mice were used as negative controls. Empty bars represent immunization groups that received prime/boost immunizations. Solid bars represent immunization groups that received priming immunization only. Mean (Ϯ standard error of the mean) numbers of SFC per 10 6 cells are shown on the y axis. The indicated immunization groups and doses are shown on the x axis. Assays were performed and analyzed with pooled lung and FRT samples as described in Materials and Methods.
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on August 27, 2017 by guest http://cvi.asm.org/ matis was effective in boosting an M. smegmatis prime, we found that boosting with recombinant M. smegmatis a second time had no effect on either anti-Env antibody levels or IFN-␥ T-cell responses (not shown). Recombinant M. smegmatis does not induce anti-HIV-1 Env antibody. Serum samples were collected 2 weeks after each recombinant M. smegmatis immunization and assayed by ELISA for antibody titers against recombinant CON6 gp140CF. We found that neither a prime nor a boost of recombinant M. smegmatis alone could induce any detectable anti-HIV-1 Env antibody (not shown).
To determine whether recombinant M. smegmatis gp120 or recombinant M. smegmatis gp140CF could prime for an Env protein boost of antibody responses to the HIV-1 envelope, mice were boosted once with recombinant CON6 gp140CF protein 4 weeks after the second immunization with recombinant M. smegmatis. We found that mice primed with recombinant M. smegmatis and boosted with CON6 gp140CF protein had significantly higher anti-Env antibody titers than mice immunized with CON6 gp140CF protein alone or mice immunized with empty recombinant M. smegmatis plus Env protein (Table 2) other modes of Env expression in recombinant M. smegmatis (P Ͻ 0.05) ( Table 2) . Next, HIV-1-specific IgG subclass responses to recombinant M. smegmatis were determined. Immunization of mice with both rAd-rVV and CON6 protein alone induced predominantly IgG1 antibodies, characteristic of a Th2-type response: the IgG1/IgG2a ratios were 4.44 and 3.59, respectively (Fig. 4) . Untransformed (empty) M. smegmatis plus CON6 Env oligomer boosting also resulted in antibody responses that were biased toward IgG1, with an IgG1/IgG2a ratio of 2.20 (Fig. 4) . Interestingly, antibody responses primed by immunizations with recombinant M. smegmatis pJH154-gp120 or pJH154-gp140CF showed a dominance of IgG2a over IgG1 antibodies (IgG1/IgG2a ratios of 0.82 and 0.49, respectively) (Fig. 4) . Thus, priming with recombinant M. smegmatis expressing HIV-1 Env or Env protein alone changed the HIV-1 isotype profile from IgG1 predominant to IgG2a predominant.
Mechanism of limitations of recombinant M. smegmatis for induction of anti-HIV-1 antibody. To determine the factors associated with the lack of induction of anti-Env antibodies by recombinant M. smegmatis, we first determined whether live recombinant M. smegmatis was immunosuppressive for Env insert antibody responses. Live recombinant M. smegmatis was mixed with 50 g of CON6 Env oligomer protein and used to immunize mice. This group of mice was compared to groups that were immunized either with 50 g CON6 Env oligomer protein alone or with heat-killed recombinant M. smegmatis plus 50 g CON6 Env. We found that recombinant M. smegmatis did not suppress anti-Env antibody responses, as the three immunogens induced similar levels of antibody responses ( 
DISCUSSION
In this study, we have shown that recombinant M. smegmatis can express full-length hypoglycosylated HIV-1 Env and that, when engineered for insert secretion, it can induce HIV-1 IFN-␥ T-cell responses in the spleen, FRT, and lungs. While unable to directly induce anti-HIV-1 Env B-cell responses, recombinant M. smegmatis was able to prime for an Env protein boost.
M. smegmatis is a rapidly growing nonpathogenic mycobacterial species that has properties that may make it a practical vector, particularly for priming for heterologous recombinant vectors or for protein boosting. M. smegmatis has been used as a model system for M. tuberculosis and for high-level expression of foreign genes (23) . Unlike other mycobacterial species, such as BCG, that survive in host cells by inhibiting phagosome maturation, M. smegmatis is rapidly destroyed by phagolysosomal proteases in the phagosomes of infected cells (16, 19) , facilitating rapid uptake of expressed antigens in M. smegmatis and cross-presentation of antigen. Recombinant M. smegmatis has been tested experimentally as a vaccine candidate for M. tuberculosis (21) , as an alternative gene expression system to BCG or M. tuberculosis (3) , and as an anticancer immunotherapy with cytokine-expressing M. smegmatis (29) . Recently, we demonstrated that recombinant M. smegmatis expressing HIV-1 HXBc2 env can generate effector, effector memory, and central memory HIV-specific CD8 T cells (2) . We also found that preexisting immunity to BCG may have only a marginal effect on the immunogenicity of recombinant M. smegmatis (2) .
Others have fused the V3 epitope of HIV-1 Env with mycobacterial antigen 85B and expressed the V3-85B fusion pro- (5, 6) . In addition, CON6 protein was equally well recognized by patient sera of multiple HIV-1 subtypes but induced a limited spectrum of anti-HIV neutralizing antibodies to subtype B primary isolates (5, 6) .
We have now produced a second-generation HIV-1 consensus Env protein, CON-S, that has shortened variable loops and induces a greater breadth of neutralizing antibodies than CON6 Env to subtype A, B, and C primary isolates (18) . Our present study was undertaken to determine whether full-length consensus CON6 Env could be expressed in recombinant M. smegmatis and, if so, whether the expressed Env was immunogenic. While anti-HIV-1 antibodies were not induced by immunization with recombinant M. smegmatis alone, it is important that recombinant M. smegmatis was able to prime for an Env oligomer boost. The experiment performed here sought to answer the question of whether fully glycosylated Env protein can boost antibody responses to conserved Env regions in hypoglycosylated Env expressed in recombinant M. smegmatis. HIV-1 neutralization assays are technically difficult to perform with mouse sera due to serum volumes and natural inhibitors of HIV-1 in mouse sera. It will be of interest to test the breadth of neutralizing antibodies induced by an M. smegmatis prime protein boost in similar experiments with guinea pigs.
To address the issue of the optimal mode of insert expression in recombinant M. smegmatis, we have tested the HIV-1 CON6 env gene that was expressed either as a surface, intracellular, or secreted antigen and determined the comparative expression levels and immunogenicities of these constructs. Differential localization of HIV envelopes within mycobacteria could affect both the timing of the immune response and the pathway of presenting antigen to the immune system. Since mycobacteria are intraphagosomal, expressed antigens in mycobacteria can be delivered into phagolysosomes and preferentially activate CD4 ϩ T cells via the major histocompatibility complex class II pathway (9) . Proteins produced within the mycobacterial cytoplasm could remain encapsulated inside the bacterium and their presentation to the host immune system delayed as long as the bacterium persists within the macrophage (14) . However, membrane-anchored and secreted antigens from M. smegmatis in the phagosome could result in earlier presentation to the immune system. The most commonly studied secreted sequence is the mycobacterial ␣-antigen (also known as MPT59 or antigen 85B), which we used to fuse the HIV-1 envelope. The other common sequence is a 19-kDa lipoprotein signal sequence that has been used to deliver the outer surface protein A (OspA) antigen of Borrelia burgdorferi to a membrane-associated lipoprotein (25) . Others have shown that protein export via ␣-antigen is inefficient and that the majority of proteins fused with ␣-antigen are associated with cell membranes (10, 17) . In our study, we demonstrated that anti-HIV-1 T-cell responses in splenocytes were optimal in mice immunized with recombinant M. smegmatis expressing HIV-1 CON6 Env engineered as secreted antigens (Fig. 3) . In addition, antibody responses against HIV-1 envelope induced by priming with recombinant M. smegmatis and boosting with CON6 Env protein were also optimal when HIV gp120 and gp140CF were expressed by recombinant M. smegmatis as secreted antigens (Table 2) .
Taken together, our data are proof of the concept that recombinant M. smegmatis vectors can induce mucosal cellular responses and prime for protein boosts of serum antibody. If the expression levels of recombinant M. smegmatis vector inserts are optimized, increased levels of immunogenicity should be attainable, and recombinant M. smegmatis may be a candidate to serve as a prime for a heterologous vector boost in an HIV-1 candidate vaccine formulation.
